pembrolizumab,sunitinib,everolimus,lenvatinib
pfizer,merck,eisai
['pembro', 'lenva', 'nct02811861', 'clear study']
updated results from asco ;the phase 2 clear study (nct02811861) show that the combination of lenvatinib/pembrolizumab sustained benefits in overall survival (os) and progression-free survival for #kidneycancer patients via 
IKCC is a Registered Foundation providing a global voice for national & regional patient support and advocacy organisations focused on kidney cancers.